Tenderwize
Wróć do wyszukiwania

Open house discount contracts for Metformin/Dapagliflozin

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2027 · 339 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-20 - Metformin/Dapagliflozin (Wirkstoffkombination)

60/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

60 / 100

Złożoność

30 / 100

Czynniki ryzyka

No estimated contract value or volume is provided, making it impossible to assess potential revenue.

Contract automatically ends upon patent expiry or loss of market exclusivity, which could occur before the planned end...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 2 lots
  • Duration until Jul 2027
  • Conclusion of discount agreements (Rabattverträge) for the fixed combination Metformin/Dapagliflozin
  • Contract term of maximum 24 months starting 01.08.2025, ending no later than 31.07.2027
Pokaż pełne podsumowanie

Open House Originale procedure by Techniker Krankenkasse (TK) for discount agreements on the fixed combination Metformin/Dapagliflozin (active substance combination) under §130c SGB V. The procedure is open to all eligible pharmaceutical entrepreneurs offering this drug. Contracts have uniform conditions, no exclusivity, and a maximum term of 24 months (01.08.2025 to 31.07.2027), subject to early termination upon patent expiry. Joining is possible at any time during the contract period. Submission is via email with qualified electronic signature or by post.

Ryzyka

No estimated contract value or volume is provided, making it impossible to assess potential revenue.

Contract automatically ends upon patent expiry or loss of market exclusivity, which could occur before the planned end...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur (Pharmazeutischer Unternehmer) as defined in §4 Abs. 18 AMG
  • Must have a valid marketing authorization for the specific drug or equivalent right to place it on the market
  • Seat must be in Germany, another EU member state, or an EEA state

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (2)

LOT-0001

No Lot Division

Discount agreement for the fixed combination Metformin/Dapagliflozin. Open to all eligible pharmaceutical entrepreneurs. Uniform conditions, no exclusivity. Contract term max 24 months from 01.08.2025, ending 31.07.2027. Joining possible anytime.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Jul 2025 - Jul 2027

Kategoria

Pharmaceutical products

LOT-0002

No Lot Split

Discount agreement for the fixed combination Metformin/Dapagliflozin. Open to all eligible pharmaceutical entrepreneurs. Uniform conditions, no exclusivity. Contract term max 24 months from 01.08.2025, ending 31.07.2027. Joining possible anytime.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Jul 2025 - Jul 2027

Kategoria

Pharmaceutical products

Szczegóły zamówienia

Data publikacji
19 May 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
324600-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3